tetano
Editor, Senior Moderator
Clin Immunol
. 2021 Jul 31;108814.
doi: 10.1016/j.clim.2021.108814. Online ahead of print.
Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection
Puya Dehgani-Mobaraki[SUP] 1 [/SUP], Asiya Kamber Zaidi[SUP] 2 [/SUP], Nidhi Yadav[SUP] 3 [/SUP], Alessandro Floridi[SUP] 4 [/SUP], Emanuela Floridi[SUP] 5 [/SUP]
Affiliations
Abstract
Better understanding of antibody responses against SARS-CoV-2 after natural infection might provide valuable insights into the future implementation of vaccination policies.Longitudinal analysis of IgG antibody titers was carried out in 32 recovered COVID-19 patients based in the Umbria region of Italy for 14 months after Mild and Moderately-Severe infection.Two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein(NCP) and anti-spike-receptor binding domain(S-RBD) were used for sequential serological tests at different time points.The demographics,clinical history and symptom profile associated with the magnitude and longevity of antibody responses were also analyzed.Anti-S-RBD IgG persisted in 96.8% (31 of 32) subjects at 14 months.Patients reporting loss of smell and taste during the clinical course of the disease developed significantly higher antibody titers.Anti-NCP IgG seronegative patients(n = 7) at 10 months,tested positive for anti-S-RBD IgG at 12,13 and 14 months emphasizing on a higher false-negative rate for NCP protein-based antibody assays.This study also highlights the importance of adopting specific immunoassays for routine estimation of antibody titers and the decreased rate of re-infections in recovered patients.
Keywords: Coronavirus; Covid19; Humoral immunity; SARS-CoV-2.
. 2021 Jul 31;108814.
doi: 10.1016/j.clim.2021.108814. Online ahead of print.
Longitudinal observation of antibody responses for 14 months after SARS-CoV-2 infection
Puya Dehgani-Mobaraki[SUP] 1 [/SUP], Asiya Kamber Zaidi[SUP] 2 [/SUP], Nidhi Yadav[SUP] 3 [/SUP], Alessandro Floridi[SUP] 4 [/SUP], Emanuela Floridi[SUP] 5 [/SUP]
Affiliations
- PMID: 34343708
- DOI: 10.1016/j.clim.2021.108814
Abstract
Better understanding of antibody responses against SARS-CoV-2 after natural infection might provide valuable insights into the future implementation of vaccination policies.Longitudinal analysis of IgG antibody titers was carried out in 32 recovered COVID-19 patients based in the Umbria region of Italy for 14 months after Mild and Moderately-Severe infection.Two FDA-approved immunoassays against SARS-CoV-2 Nucleocapsid protein(NCP) and anti-spike-receptor binding domain(S-RBD) were used for sequential serological tests at different time points.The demographics,clinical history and symptom profile associated with the magnitude and longevity of antibody responses were also analyzed.Anti-S-RBD IgG persisted in 96.8% (31 of 32) subjects at 14 months.Patients reporting loss of smell and taste during the clinical course of the disease developed significantly higher antibody titers.Anti-NCP IgG seronegative patients(n = 7) at 10 months,tested positive for anti-S-RBD IgG at 12,13 and 14 months emphasizing on a higher false-negative rate for NCP protein-based antibody assays.This study also highlights the importance of adopting specific immunoassays for routine estimation of antibody titers and the decreased rate of re-infections in recovered patients.
Keywords: Coronavirus; Covid19; Humoral immunity; SARS-CoV-2.